Smoking CessationPhase 2NCT04887558
Mobile App for Smoking Cessation and Mental Health
A Phase 2 study testing Smart-T Mental Health and NRT, Smart-T Mental Health+ and NRT and QuitGuide + NRT in people with Smoking Cessation and Mental Illness, run by University of Oklahoma at 1 site in United States.
Trial summary
Adults with serious mental illness (SMI) represent 5% of the United States population, yet account for 30% of all cigarettes smoked and are 2 to 3 times more likely to be dependent on nicotine compared with the general population. Read more about this study
- Who is it for?
- Ages 18 to 100 yearsHealthy volunteers can take part
- Conditions the study is for
- Smoking Cessation, Mental Illness
- What is being tested?
- Smart-T Mental Health and NRT, Smart-T Mental Health+ and NRT and QuitGuide + NRT
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 1 siteUnited States
- Study dates
- 14 Dec 2021to Dec 2028
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- valid residential address to mail study materials
- earn a score ≥ 4 on the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF) indicating > 6th grade English literacy level (required to complete EMAs; at least 88% of all individuals screened for our EMA studies have met this inclusion criterion)
- willingness to quit smoking 7 days after the randomization phone call
- currently smoke ≥ 10 cigarettes per day
- willing and medically eligible to use combination NRT
- agree to complete daily EMAs and thrice-weekly CO tests on a study provided or personal smartphone
- agree to complete the 5-week post-quit follow-up assessment (i.e., smartphone based quantitative survey and qualitative interview via phone call).
Who cannot join
- Individuals who score ≥ 8 on the Cognitive Impairment Test, which indicates severe cognitive impairment,
- Pregnant or intend to become pregnant during the study period.
Trial locations and contacts
1 site in 1 country.
United States1 site
Oklahoma Department of Mental Health and Substance Abuse Services
Oklahoma City, Oklahoma, 73105
About this study
Official title: Smartphone-Based Smoking Cessation and Mental Health Intervention
Adults with serious mental illness (SMI) represent 5% of the United States population, yet account for 30% of all cigarettes smoked and are 2 to 3 times more likely to be dependent on nicotine compared with the general population. There are also significant disparities in quitting: 24% of lifetime smokers with SMI report not smoking within the past year compared with 52% of lifetime smokers without SMI. Two barriers partly explain the large disparity in smoking cessation rates between adults with and without SMI. First, there is a lack of high-quality, evidence-based interventions for smoking cessation in populations with SMI, which may be because adults with SMI are often excluded from clinical trials, despite evidence indicating that SMI is highly comorbid with smoking. Second, clinicians and staff within mental health settings generally do not have the resources or appropriate training to provide smoking cessation treatments to patients with SMI. Smartphone-based mobile health applications for smoking cessation could significantly improve cessation rates for adults with SMI. However, smoking cessation apps are underutilized by smokers with SMI partly because the apps are not designed for their unique needs. This study aims to conduct a pilot randomized controlled trial to evaluate the feasibility of an innovative, evidence-based smoking cessation app tailored for smokers with SMI. Seventy-five treatment-seeking smokers with SMI who will be referred from the Oklahoma Department of Mental Health and Substance Abuse Services (25 per group), a publicly funded outpatient psychiatry treatment program, will be randomly assigned to receive either (1) QuitGuide, a free smoking cessation app developed by the National Cancer Institute, (2) a smoking cessation app that tracks and automatically intervenes upon psychological distress during a quit attempt and delivers real-time intervention messages tailored to the current level of lapse risk and current lapse triggers (Smart-T Mental Health; STMH), or (3) the STMH app with additional messaging focused on increasing adherence to nicotine replacement medications (STMH+). All study conditions will be followed for 5 weeks (1-week pre-cessation and 4 weeks post-cessation), receive nicotine replacement therapy, and complete smartphone-based survey assessments using ecological momentary assessment procedures.
Read the detailed description
SPECIFIC AIMS
Cigarette smoking is the leading preventable cause of morbidity and mortality in the United States. Smokers with serious mental illness (SMI; e.g., schizophrenia, bipolar disorder, major depressive disorder, anxiety disorders) have an increased risk of dying from cancer, lung disease, and cardiovascular disease and account for more than 200,000 of the 520,000 tobacco-related deaths each year. Many studies have shown that smoking rates are 2-5 times higher in adults with SMI compared with adults with no mental illness. People with SMI smoke more frequently and heavily than the general population, and they often lack access to cessation services. Furthermore, smokers with SMI are more dependent on nicotine and are less likely to quit than those without SMI. Thus, smoking and smoking cessation in this population are critical public health concerns that warrant further study.
Although there is substantial evidence for the effectiveness of multiple smoking cessation treatments for the general population of smokers, these interventions tend to be less effective or not effective at all when provided to smokers with SMI. Thus, while smoking rates among those without a history of SMI has radically declined over the past 5 decades, smoking prevalence among those with SMI has remained alarmingly high over this same time period. While several studies have identified some reasons for disparities in smoking cessation treatment effectiveness in adults with SMI, understanding of the complex causes of this known and growing disparity remains limited. A more granular examination of the cessation, lapse, and relapse process among adult smokers with SMI is needed: 1) to improve understanding of smoking cessation in this vulnerable and understudied population, and 2) to inform the development of more effective interventions for this underserved population. Smartphone-based Ecological Momentary Assessments (EMA) have been used to identify antecedents to smoking lapse in various populations. Just-in-Time Adaptive Interventions (JITAI) that provide tailored treatment content for adults with SMI in moments when it is needed most may offer cost-effective, easily accessible, highly tailored interventions in free-living settings. To date, four smartphone-based smoking cessation JITAIs have been created, and pilot tested in SMI samples. Yet, few JITAI for SMI populations have been investigated regarding their acceptability, feasibility, and usefulness.
The long-term goal of this research is to increase smoking cessation rates of smokers with SMI using a smartphone-based mobile health application. The primary objective of this study, which is the next step towards achieving this long-term objective, is to conduct a pilot randomized controlled trial (RCT) to evaluate the feasibility of an innovative smoking cessation app that has been tailored for smokers with SMI. Seventy-five treatment-seeking smokers with SMI, referred from the Oklahoma Department of Mental Health and Substance Abuse Services (ODMH),49 will be randomly assigned to receive either (1) QuitGuide,50 a free smoking cessation app developed by the National Cancer Institute (NCI), (2) a smoking cessation app that tracks and automatically intervenes upon psychological distress in real-time during a quit attempt and delivers real-time intervention messages tailored to the current level of lapse risk and current lapse triggers (i.e., Smart-T Mental Health; STMH), or (3) STMH with additional nicotine replacement therapy adherence messaging (STMH+). Participants in both study conditions will be followed for 5 weeks (1-week pre-cessation and 4 weeks post-cessation), receive nicotine replacement therapy (NRT), and complete smartphone-based ecological momentary assessments (EMA). The primary objective of this study will be attained by pursuing the following specific aims.
Determine the feasibility, ease of use, and perceived utility of a smoking cessation app designed for adults with SMI.
Determine preliminary estimates of the impact of treatment condition (i.e., STMH vs. STMH+ vs. QuitGuide app; n=25 per group) on biochemically verified smoking abstinence.
. Determine the effect of the STMH treatment messages on key lapse risk factors.
Use qualitative interviews to examine perceptions of the STMH, STMH+, and QuitGuide smoking cessation apps.
STUDY OVERVIEW
Eligible and interested individuals (N = 75) will be randomized to 1 of 3 groups: 1) smartphone-based smoking cessation intervention designed for adults with serious mental illness (STMH) with NRT, 2) STMH plus additional NRT adherence messaging (STMH+) with NRT, or 3) NCI QuitGuide, a smartphone-based smoking cessation intervention designed for the general population with NRT. Participants will be followed for 5 weeks, and the entire intervention will be accessed remotely through personal or study provided smartphones, independently or with assistance from study staff. Participants will be prompted to complete daily EMAs and thrice-weekly smoking status tests using a portable, low-cost carbon monoxide monitor (Bedfont iCO Smokerlyzer). These data will be used to address primary (i.e., biochemically verified 7-day point prevalence abstinence at 4 weeks post-quit, number of days of abstinence during the 4 week post-quit period) and secondary outcomes (e.g., 28-day point prevalence abstinence, number of days to first lapse, the longest period of smoking abstinence). We have already created software that integrates the iCO sensor into our InsightTM mHealth platform.
IMPORTANCE OF KNOWLEDGE REASONABLY EXPECTED TO RESULT FROM THE RESEARCH
Although many smartphone based smoking cessation apps exist, very few have been developed for smokers with serious mental illness. This study is the first step towards developing a line of research that aims to develop and disseminate effective and automated treatments for smoking cessation for this underserved and understudied population. Thus, the knowledge that will be gained from this study is important. Furthermore, the Smart-T Mental Health app will allow us to reach a population that frequently lacks access to traditional intervention programs, due to limited availability, income, and/or transportation, among other barriers. In addition, the proposed smartphone app is highly versatile and may be easily modified for use in other populations or communities. The risks to subjects are minimal, especially considering the protections against risks that will be implemented for this study.
- Conditions
- Smoking Cessation, Mental Illness
- Being tested
- Smart-T Mental Health and NRT, Smart-T Mental Health+ and NRT, QuitGuide + NRT
- Medical subject headings
- Smoking Cessation, Mental Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Smart-T Mental Health and NRTCombination product
Smart-Treatment Mental Health App and Nicotine Replacement Therapy
Smart-T Mental Health+ and NRTCombination product
Smart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy
QuitGuide + NRTCombination product
NCI QuitGuide Treatment App and Nicotine Replacement Therapy
| Study group | Role | What they receive |
|---|---|---|
| NCI QuitGuide and NRT | Active comparator | The National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free NRT. Receives: Combination Product: QuitGuide + NRT |
| Smart-T Mental Health and NRT | Experimental | Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive NRT. Receives: Combination Product: Smart-T Mental Health and NRT |
| Smart-T Mental Health+ and NRT | Experimental | Smart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. During the pre-quit and post-quit period, the app will also send messages that encourage the use of the nicotine patch and lozenges according to recommended practices. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free NRT. Receives: Combination Product: Smart-T Mental Health+ and NRT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Biochemically-Verified Smoking Cessation
Biochemically confirmed 7-day point prevalence abstinence using the CO criteria cutoff of ≤ 7 ppm
Measured: 4 weeks
Secondary outcomes (8)
Change in smoking urge
Ecological momentary assessment measures of smoking urge (single question, "I have an urge to smoke" - strongly disagree to strongly agree)
Measured: 4 weeks
Change in stress
Ecological momentary assessment measures of stress (single question, "I feel stressed" - strongly disagree to strongly agree)
Measured: 4 weeks
Change in cigarette availability
Ecological momentary assessment measures of cigarette availability (single question, "Cigarettes are available to me" - not at all to easily available)
Measured: 4 weeks
Change in cessation motivation
Ecological momentary assessment measures of cessation motivation (i.e., I am motivated to avoid smoking)
Measured: 4 weeks
Change in depression
Ecological momentary assessment measures of depression (i.e., Rate your current level of depression [feeling sad])
Measured: 4 weeks
Change in anxiety
Ecological momentary assessment measures of anxiety (i.e., Rate your current level of anxiety [feeling nervous])
Measured: 4 weeks
Change in nicotine patch use
Ecological momentary assessment measures nicotine wear time (i.e., Are you wearing a patch right now?)
Measured: 4 weeks
Change in lozenge use
Ecological momentary assessment measures nicotine wear time (i.e., Have you used a nicotine lozenge in the past hour? )
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2021
- Study start14 Dec 2021
- Primary completion6 Jan 2026
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Smoking CessationStudies of the same condition, open and under way.
- More trials run by University of OklahomaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oklahoma
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Michael Businelle, PhD, Study director, TSET Health Promotion Research Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04887558
- Sponsor's protocol ID
- 13388
- Status last verified
- Apr 2026
- First submitted
- 10 May 2021
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be available by requesting it from the senior investigator, Dr. Michael Businelle
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Smartphone-Based Smoking Cessation and Mental Health Intervention
- ClinicalTrials.gov ID
- NCT04887558
- Acronym / sponsor ID
- 13388
- Conditions
- Smoking Cessation, Mental Illness
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 64 participants (actual)
- Lead sponsor
- University of OklahomaUniversity, hospital or other
- Study start
- 14 Dec 2021 (actual)
- Primary completion
- 6 Jan 2026 (actual)
- Study completion
- Dec 2028 (estimated)
- First posted
- 14 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adults with serious mental illness (SMI) represent 5% of the United States population, yet account for 30% of all cigarettes smoked and are 2 to 3 times more likely to be dependent on nicotine compared with the general population. There are also significant disparities in quitting: 24% of lifetime smokers with SMI report not smoking within the past year compared with 52% of lifetime smokers without SMI. Two barriers partly explain the large disparity in smoking cessation rates between adults with and without SMI. First, there is a lack of high-quality, evidence-based interventions for smoking cessation in populations with SMI, which may be because adults with SMI are often excluded from clinical trials, despite evidence indicating that SMI is highly comorbid with smoking. Second, clinicians and staff within mental health settings generally do not have the resources or appropriate training to provide smoking cessation treatments to patients with SMI. Smartphone-based mobile health applications for smoking cessation could significantly improve cessation rates for adults with SMI. However, smoking cessation apps are underutilized by smokers with SMI partly because the apps are not designed for their unique needs. This study aims to conduct a pilot randomized controlled trial to evaluate the feasibility of an innovative, evidence-based smoking cessation app tailored for smokers with SMI. Seventy-five treatment-seeking smokers with SMI who will be referred from the Oklahoma Department of Mental Health and Substance Abuse Services (25 per group), a publicly funded outpatient psychiatry treatment program, will be randomly assigned to receive either (1) QuitGuide, a free smoking cessation app developed by the National Cancer Institute, (2) a smoking cessation app that tracks and automatically intervenes upon psychological distress during a quit attempt and delivers real-time intervention messages tailored to the current level of lapse risk and current lapse triggers (Smart-T Mental Health; STMH), or (3) the STMH app with additional messaging focused on increasing adherence to nicotine replacement medications (STMH+). All study conditions will be followed for 5 weeks (1-week pre-cessation and 4 weeks post-cessation), receive nicotine replacement therapy, and complete smartphone-based survey assessments using ecological momentary assessment procedures.
Detailed description
SPECIFIC AIMS
Cigarette smoking is the leading preventable cause of morbidity and mortality in the United States. Smokers with serious mental illness (SMI; e.g., schizophrenia, bipolar disorder, major depressive disorder, anxiety disorders) have an increased risk of dying from cancer, lung disease, and cardiovascular disease and account for more than 200,000 of the 520,000 tobacco-related deaths each year. Many studies have shown that smoking rates are 2-5 times higher in adults with SMI compared with adults with no mental illness. People with SMI smoke more frequently and heavily than the general population, and they often lack access to cessation services. Furthermore, smokers with SMI are more dependent on nicotine and are less likely to quit than those without SMI. Thus, smoking and smoking cessation in this population are critical public health concerns that warrant further study.
Although there is substantial evidence for the effectiveness of multiple smoking cessation treatments for the general population of smokers, these interventions tend to be less effective or not effective at all when provided to smokers with SMI. Thus, while smoking rates among those without a history of SMI has radically declined over the past 5 decades, smoking prevalence among those with SMI has remained alarmingly high over this same time period. While several studies have identified some reasons for disparities in smoking cessation treatment effectiveness in adults with SMI, understanding of the complex causes of this known and growing disparity remains limited. A more granular examination of the cessation, lapse, and relapse process among adult smokers with SMI is needed: 1) to improve understanding of smoking cessation in this vulnerable and understudied population, and 2) to inform the development of more effective interventions for this underserved population. Smartphone-based Ecological Momentary Assessments (EMA) have been used to identify antecedents to smoking lapse in various populations. Just-in-Time Adaptive Interventions (JITAI) that provide tailored treatment content for adults with SMI in moments when it is needed most may offer cost-effective, easily accessible, highly tailored interventions in free-living settings. To date, four smartphone-based smoking cessation JITAIs have been created, and pilot tested in SMI samples. Yet, few JITAI for SMI populations have been investigated regarding their acceptability, feasibility, and usefulness.
The long-term goal of this research is to increase smoking cessation rates of smokers with SMI using a smartphone-based mobile health application. The primary objective of this study, which is the next step towards achieving this long-term objective, is to conduct a pilot randomized controlled trial (RCT) to evaluate the feasibility of an innovative smoking cessation app that has been tailored for smokers with SMI. Seventy-five treatment-seeking smokers with SMI, referred from the Oklahoma Department of Mental Health and Substance Abuse Services (ODMH),49 will be randomly assigned to receive either (1) QuitGuide,50 a free smoking cessation app developed by the National Cancer Institute (NCI), (2) a smoking cessation app that tracks and automatically intervenes upon psychological distress in real-time during a quit attempt and delivers real-time intervention messages tailored to the current level of lapse risk and current lapse triggers (i.e., Smart-T Mental Health; STMH), or (3) STMH with additional nicotine replacement therapy adherence messaging (STMH+). Participants in both study conditions will be followed for 5 weeks (1-week pre-cessation and 4 weeks post-cessation), receive nicotine replacement therapy (NRT), and complete smartphone-based ecological momentary assessments (EMA). The primary objective of this study will be attained by pursuing the following specific aims.
Determine the feasibility, ease of use, and perceived utility of a smoking cessation app designed for adults with SMI.
Determine preliminary estimates of the impact of treatment condition (i.e., STMH vs. STMH+ vs. QuitGuide app; n=25 per group) on biochemically verified smoking abstinence.
. Determine the effect of the STMH treatment messages on key lapse risk factors.
Use qualitative interviews to examine perceptions of the STMH, STMH+, and QuitGuide smoking cessation apps.
STUDY OVERVIEW
Eligible and interested individuals (N = 75) will be randomized to 1 of 3 groups: 1) smartphone-based smoking cessation intervention designed for adults with serious mental illness (STMH) with NRT, 2) STMH plus additional NRT adherence messaging (STMH+) with NRT, or 3) NCI QuitGuide, a smartphone-based smoking cessation intervention designed for the general population with NRT. Participants will be followed for 5 weeks, and the entire intervention will be accessed remotely through personal or study provided smartphones, independently or with assistance from study staff. Participants will be prompted to complete daily EMAs and thrice-weekly smoking status tests using a portable, low-cost carbon monoxide monitor (Bedfont iCO Smokerlyzer). These data will be used to address primary (i.e., biochemically verified 7-day point prevalence abstinence at 4 weeks post-quit, number of days of abstinence during the 4 week post-quit period) and secondary outcomes (e.g., 28-day point prevalence abstinence, number of days to first lapse, the longest period of smoking abstinence). We have already created software that integrates the iCO sensor into our InsightTM mHealth platform.
IMPORTANCE OF KNOWLEDGE REASONABLY EXPECTED TO RESULT FROM THE RESEARCH
Although many smartphone based smoking cessation apps exist, very few have been developed for smokers with serious mental illness. This study is the first step towards developing a line of research that aims to develop and disseminate effective and automated treatments for smoking cessation for this underserved and understudied population. Thus, the knowledge that will be gained from this study is important. Furthermore, the Smart-T Mental Health app will allow us to reach a population that frequently lacks access to traditional intervention programs, due to limited availability, income, and/or transportation, among other barriers. In addition, the proposed smartphone app is highly versatile and may be easily modified for use in other populations or communities. The risks to subjects are minimal, especially considering the protections against risks that will be implemented for this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| NCI QuitGuide and NRT | Active comparator | Combination Product: QuitGuide + NRTThe National Cancer Institute's QuitGuide app is a free smartphone app and is one of few apps that includes many of the recommendations detailed in the Clinical Practice Guideline. The QuitGuide app aims to help smokers understand their smoking patterns and develop the skills needed to quit smoking. QuitGuide provides content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. All participants will receive free NRT. |
| Smart-T Mental Health and NRT | Experimental | Combination Product: Smart-T Mental Health and NRTSmart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive NRT. |
| Smart-T Mental Health+ and NRT | Experimental | Combination Product: Smart-T Mental Health+ and NRTSmart-T Mental Health provides smoking cessation and mental health content during the pre-quit and post-quit periods to prepare and support participants during their quit attempt. During the pre-quit and post-quit period, the app will also send messages that encourage the use of the nicotine patch and lozenges according to recommended practices. The Smart-T app contains multiple components including an EMA delivery and data transfer system, automated messages based upon EMA responses, and on-demand content. All participants will receive free NRT. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- valid residential address to mail study materials
- earn a score ≥ 4 on the Rapid Estimate of Adult Literacy in Medicine-Short Form (REALM-SF) indicating > 6th grade English literacy level (required to complete EMAs; at least 88% of all individuals screened for our EMA studies have met this inclusion criterion)
- willingness to quit smoking 7 days after the randomization phone call
- currently smoke ≥ 10 cigarettes per day
- willing and medically eligible to use combination NRT
Key exclusion criteria (2 listed)
- Individuals who score ≥ 8 on the Cognitive Impairment Test, which indicates severe cognitive impairment,
- Pregnant or intend to become pregnant during the study period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Smart-T Mental Health and NRTSmart-Treatment Mental Health App and Nicotine Replacement Therapy | Combination product | Smart-T Mental Health and NRT |
| Smart-T Mental Health+ and NRTSmart-Treatment Mental Health App+NRT adherence messages and Nicotine Replacement Therapy | Combination product | Smart-T Mental Health+ and NRT |
| QuitGuide + NRTNCI QuitGuide Treatment App and Nicotine Replacement Therapy | Combination product | NCI QuitGuide and NRT |
Primary outcome
Biochemically-Verified Smoking Cessation
Time frame: 4 weeks
Biochemically confirmed 7-day point prevalence abstinence using the CO criteria cutoff of ≤ 7 ppm
8 secondary outcomes
Change in smoking urge
Time frame: 4 weeks
Change in stress
Time frame: 4 weeks
Change in cigarette availability
Time frame: 4 weeks
Change in cessation motivation
Time frame: 4 weeks
Change in depression
Time frame: 4 weeks
Change in anxiety
Time frame: 4 weeks
Change in nicotine patch use
Time frame: 4 weeks
Change in lozenge use
Time frame: 4 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Individual participant dataSharing planned: No. Data will be available by requesting it from the senior investigator, Dr. Michael Businelle
Related trials for Smoking Cessation
Enrolling by invitationObservational study
Using Smartwatches to Monitor Smoking in Real-life Situations
Smoking
Not yet recruitingObservational study
PROMETHEE: A Shared Interregional Tele-Tobacco Cessation Platform Embedded Within the IMPULSION Lung Cancer Screening Program
Smoking Cessation, Lung Cancer Screening
Not yet recruiting
Impacto 2.0: Mobile Smoking Cessation Across Texas
Cigarette Smoking, Smoking Cessation
Not yet recruiting
Smoking Cessation Program for Lao People With HIV
Smoking Cessation, HIV
RecruitingPhase 3
Studying NMDA and Sigma-1 in Smoking Cessation Treatment (SUMMIT)
Smoking Cessation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Businelle, PhD study director
TSET Health Promotion Research Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Smart-T Mental Health and NRT, Smart-T Mental Health+ and NRT and QuitGuide + NRT in people with Smoking Cessation and Mental Illness, run by University of Oklahoma at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Biochemically-Verified Smoking Cessation (time frame: 4 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.